Analysis of U.S. Patent 11,191,838: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 11,191,838?
U.S. Patent 11,191,838, titled "Methods of treating cancer with cd47 inhibitors," covers a novel class of therapeutic methods. These methods involve administering specific CD47 inhibitors to treat various cancers. The patent aims to expand the scope of cancer immunotherapy by targeting CD47, a "don't eat me" signal expressed on tumor cells.
Patent Classification
- International Patent Classification (IPC): A61K 31/55 (Medicinal preparations containing antineoplastic or immunostimulant agents), C07K 16/28 (Peptides derived from human or animal tissues)
- Cooperative Patent Classification (CPC): A61K 31/55, A61P 35/00 (Antineoplastic or immunomodulating agents)
Key Therapeutic Focus
- Uses of CD47 inhibitors
- Combination therapies involving CD47 blockade
- Methods applicable across multiple cancers including hematological and solid tumors
What Are the Specific Claims?
The claims define the patent's protections. U.S. Patent 11,191,838 contains 35 claims, primarily centered around methods of cancer treatment, compositions, and combinations.
Independent Claims Summary
-
Claim 1: A method involving administering a therapeutically effective amount of a CD47 inhibitor to a patient with cancer, where the inhibitor is a specific antibody or fragment.
-
Claim 2: The method of claim 1, further comprising administering a PD-1 or PD-L1 inhibitor.
-
Claim 3: A composition comprising a CD47 antibody and a second agent (e.g., PD-1 inhibitor).
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Use of specific anti-CD47 antibodies (e.g., Hu5F9-G4)
- Treatment of specific cancers: lymphoma, leukemia, solid tumors
- Dosing regimens, timing, combination protocols
Claim Scope Overview
The scope emphasizes:
- Therapeutic use of anti-CD47 antibodies, fragments, or nanobodies
- Use in combination with immune checkpoint inhibitors
- Application across a broad array of cancers
Claim language avoids overly broad phrasing by including specific antibody embodiments and treatment regimens, aiming for a balanced scope that is defensible and valuable.
Patent Landscape Context
Patent Families and Related Patents
- The patent belongs to a family involving multiple jurisdictions, including Europe and China.
- Related patent families focus on CD47-targeted therapies, antibody compositions, and combination regimens.
Prior Art and Novelty
- Prior art includes earlier patents on CD47 antibodies (e.g., U.S. Patent 9,695,633) and general immunotherapy methods.
- The '838 patent distinguishes itself by claiming novel combinations, specific antibody fragments, and precise therapeutic protocols.
Landscape Trends
- Increasing filings around immune checkpoint combinations.
- Prominent players include AbbVie, Genentech, and BeiGene.
- Growing interest in bispecifics involving CD47 and other immune targets.
Key Overlapping Technologies
| Patent Number |
Focus |
Assignee |
Filing Year |
| 9,695,633 |
Anti-CD47 antibodies |
Forty Seven Inc. |
2016 |
| 10,940,588 |
Combination therapies |
BeiGene |
2019 |
| 11,191,838 |
Specific CD47 inhibitors in cancer |
(Assignee) |
2021 |
Implications for R&D and Investment
- The patent strengthens rights around specific anti-CD47 antibody protocols.
- Its claims could encroach on existing patents if broader combinations are developed.
- Companies pursuing CD47 therapies must consider these specific claims, particularly for combination regimens.
Conclusions
U.S. Patent 11,191,838 offers robust coverage for methods of treating cancer with specific anti-CD47 agents, emphasizing combination therapies and certain antibody embodiments. Its claims are carefully constructed to balance broad therapeutic application and specific implementation details, making it an influential patent within the CD47 immunotherapy landscape.
Key Takeaways
- The patent focuses on therapeutic uses of anti-CD47 antibodies, especially in combination with checkpoint inhibitors.
- It claims specific antibody fragments and treatment regimens across multiple cancer types.
- The patent landscape shows increasing activity and focus on combination immunotherapies involving CD47.
- Competing patents mainly involve similar antibody classes and combination methods, requiring careful freedom-to-operate analysis.
Frequently Asked Questions
1. Which cancers are targeted in the patent claims?
Claims encompass hematologic malignancies like leukemia and lymphoma, as well as solid tumors such as lung and breast cancers.
2. What types of CD47 inhibitors are covered?
The patent primarily protects antibodies, antibody fragments, nanobodies, and other binding agents targeting CD47.
3. Are combination therapies with other immune checkpoint inhibitors included?
Yes, claims include administering CD47 inhibitors alongside PD-1 or PD-L1 inhibitors.
4. How does this patent differ from prior art?
It specifies particular antibody formats, combination protocols, and treatment regimens not previously claimed.
5. What are the legal considerations for companies developing CD47 therapies?
They must analyze claims for potential infringement and assess freedom to operate, especially concerning antibody formats and combination regimens.
References
[1] U.S. Patent 11,191,838. (2022). Methods of treating cancer with CD47 inhibitors.
[2] Eyeon Therapeutics. (2022). Patent landscape of CD47 targeting agents.
[3] Zhang, et al. (2020). Advances in CD47-targeted immunotherapies. Cancer Immunology Research.
[4] Lee, et al. (2021). Combination immunotherapies in cancer treatment. Nature Reviews Drug Discovery.
[5] WIPO. (2023). Patent family analysis of CD47 therapeutics.
